Simplified controlled studies in new regions for safety concern arising from using foreign safety data

Drug Information Journal

Volumn 40, Issue 4, 2006, Pages 365-369

  Lin, Yeong Liang ^a   Wu, Chien Hua ^b   Chan, K Arnold ^c  

^a Center for Drug Evaluation   (Taiwan)

^b CHUNG YUAN CHRISTIAN UNIVERSITY   (Taiwan)

^c HARVARD SCHOOL OF PUBLIC HEALTH   (United States)

Author keywords

E5; Ethnic factor; Hepatic; ICH; Safety

Indexed keywords

ANTIDIABETIC AGENT; IBUPROFEN; INDOMETACIN; METFORMIN; NAPROXEN; ROFECOXIB; SALBUTAMOL; SALMETEROL; SULFONYLUREA DERIVATIVE; SULINDAC; TROGLITAZONE;

ARTICLE; ASIA; CLINICAL TRIAL; COST EFFECTIVENESS ANALYSIS; DRUG APPROVAL; DRUG MARKETING; DRUG SAFETY; DRUG WITHDRAWAL; ETHNIC DIFFERENCE; EVIDENCE BASED MEDICINE; GASTROINTESTINAL TOXICITY; HUMAN; LACTIC ACIDOSIS; LIVER TOXICITY; METHODOLOGY; OUTCOME ASSESSMENT; PATIENT SELECTION; PHARMACOEPIDEMIOLOGY; PRACTICE GUIDELINE; PRIORITY JOURNAL; RACE DIFFERENCE; UNSPECIFIED SIDE EFFECT;

EID: 33750886300     PISSN: 00928615     EISSN: None     Source Type: Journal    
DOI: 10.1177/216847900604000401     Document Type: Article

References (18)

1. Naito C. Necessity and requirements of bridging studies and their present status in Japan. Int J Clin Pharmacol Ther. 2000;38:80-86.
2. International Conference on Harmonisation of Technical Requirements for Registration of Pharmaceuticals for Human Use. ICH Harmonised Tripartite Guideline: Ethnic Factors for the Acceptability of Foreign Clinical Data (E5). Geneva, Switzerland: International Conference on Harmonisation; 1996.
3. Lin YL, Chiou YJ, Hsiao CL, et al. Assessment of extrapolation of foreign clinical data as a basis for registration purposes. Drug Inf J. 2002;36:513-156.
4. Lin YL, Chern HD, Chu ML. Taiwan's experience with the assessment of the acceptability of the extrapolation of foreign clinical data for registration purposes. Drug Inf J. 2003;37:143-145.
5. Guideline for good epidemiology practices for drugs, device and vaccine research in the United States, International Society for Pharmacoepidemiology 1996. Available at: http://www.pharmacoepi.org/resources/goodprac.htm. Accessed September 13, 2004.
6. US Food and Drug Administration. Guidance for industry-good pharmacovigilance practices and pharmacoepidemiologic assessment. Available at: http://www.fda.gov/cder/guidance/5767dft.pdf. Accessed September 23, 2004.
7. US Food and Drug Administration. Guidance for industry-premarketing risk assessment. Available at: http://www.fda.gov/cder/guidance/5765dft.pdf. Accessed September 23, 2004.
8. US Food and Drug Administration. Special interest topic: phase IV protocol of glucophage (NDA 20-357). Available at: http://www.fda.gov/cder/fi/ special/97/phase4prot_glucophagel.pdf. Accessed December 8, 2004.
9. Castle W, Fuller R, Hall J, et al. Serevent nationwide surveillance study: comparison of salmeterol with salbutamol in asthmatic patients who require regular bronchodilator treatment. BMJ. 1993;306:1034-1037.
10. International Conference on Harmonisation of Technical Requirements for Registration of Pharmaceuticals for Human Use. ICH Harmonised Tripartite Guideline: Choice of Control Group and Related Issues in Clinical Trials (E10). Geneva, Switzerland: International Conference on Harmonisation; 2000.
11. Hawkey C, Laine L, Simon T, et al. Comparison of the effect of rofecoxib (a cyclooxygenase 2 inhibitor), ibuprofen, and placebo on the gastroduodenal mucosa of patients with osteoarthritis: a randomized, controlled, double-blind, placebo-controlled trial. Arthritis Rheum. 2000;43:370-377.
12. Bombardier C, Laine L, Reicin A, et al. Comparison of upper gastrointestinal toxicity of rofecoxib and naproxen in patients with rheumatoid arthritis. N Engl J Med. 2000;343:1520-1528.
13. Zawadzki JK, Green L, Graham DJ. Thiazolidine-dione-associated 15-month postmarketing hepatotoxicity. FDA Science Forum. Available at: http://www.cfsan.fda.gov/~frf/forum02/a187ab 4.htm. Accessed November 18, 2004.
14. Amacher DE. Serum transaminase elevations as indicators of hepatic injury administration of drugs. Regul Toxicol Pharmacol. 1998;27:119-130.
15. US Food and Drug Administration. PhRMA/FDA/AASLD drug-induced hepatotoxicity white paper clinical considerations. Available at: http://www .fda.goy/cder/livertox/clinical.pdf. Accessed December 8, 2004.
16. Aithal PG, Day CP. The natural history of histologically proved drug induced liver disease. Gut. 1999;44:731-735.
17. Teoh NC, Farrell GC. Hepatotoxicity associated with non-steroidal anti-inflammatory drugs. Clin Liver Dis. 2003;7:401-413.
18. Tolman GK, Chandramouli J. Hepatotoxicity of the thiazolidinediones. Clin Liver Dis. 2003;7:369-379.